Medications

Linagliptin noninferior for CV risk in early type 2 diabetes

(HealthDay)—Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical ...

Medical research

Empagliflozin doesn't up risk of bone fractures

(HealthDay)—Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.

Diseases, Conditions, Syndromes

New oral diabetes drugs may also protect patients' kidney health

A recent study indicates that a new class of oral diabetes drugs may help protect patients' kidney health in addition to lowering their blood sugar levels. The findings appear in an upcoming issue of the Journal of the American ...

Diabetes

Study highlights third-line treatment options for T2DM

(HealthDay)—Treatment escalation options have different efficacy following failure of exenatide or glimepiride added to metformin in patients with type 2 diabetes mellitus, according to a study published online April 1 ...

Medications

Added benefit of lixisenatide is not proven

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together ...

Medications

Added benefit of dapagliflozin is not proven

Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Medications

Added benefit of saxagliptin/metformin combination is not proven

The fixed combination of the drugs saxagliptin and metformin (Komboglyze) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act ...

Medications

Linagliptin: Once again, no proof of added benefit

Linagliptin (trade name Trajenta) has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market ...

Diabetes

Linagliptin noninferior to glimepiride in type 2 diabetes

(HealthDay) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.

page 1 from 1